<DOC>
	<DOCNO>NCT01856907</DOCNO>
	<brief_summary>Gestational diabetes mellitus ( GDM ) define `` degree glucose intolerance onset first recognition pregnancy . '' GDM one frequent metabolic disorder occur pregnancy . Approximately 7 % pregnancy United States complicate gestational diabetes result 200,000 case annually . There epidemiologic evidence associate GDM insulin resistance , glucose intolerance , type 2 diabetes ( DM2 ) . Among risk factor diabetes mellitus , experience gestational diabetes strong one . Systematic review old study conclude 35-60 % woman gestational diabetes develop type 2 diabetes rate much great control group glucose intolerance pregnancy . Studies need optimal postpartum long-term health woman GDM . Recent evidence suggest incretin-based therapy may useful treatment DM2 continuous administration glucagon-like peptide 1 ( GLP-1 ) produce substantial improvement glucose control ß-cell function subject DM2 . Inhibition dipeptidyl peptidase-4 ( DPP-4 ) increase concentration GLP-1 may potentially delay disease progression GDM consider ß-cell function improvement DM2 ß-cell mass show increase animal model . This study examine combination sitagliptin ( DPP-4 inhibitor ) -plus metformin effective metformin alone placebo improve metabolic parameter , specifically impact β-cell function , prior GDM woman glucose abnormality .</brief_summary>
	<brief_title>Sitagliptin + Metformin Compared Metformin Monotherapy Placebo Women With Recent GDM</brief_title>
	<detailed_description>Gestational diabetes mellitus ( GDM ) define `` degree glucose intolerance onset first recognition pregnancy . '' GDM one frequent metabolic disorder occur pregnancy . Approximately 7 % pregnancy United States complicate gestational diabetes result 200,000 case annually . There epidemiologic evidence associate GDM insulin resistance , glucose intolerance , type 2 diabetes ( DM2 ) . Among risk factor diabetes mellitus , experience gestational diabetes strong one . Gestational diabetes often culmination year unrecognized unmodified diabetes risk factor lead overt occult clinical manifestation pregnancy . Systematic review old study conclude 35-60 % woman gestational diabetes develop type 2 diabetes rate much great control group glucose intolerance pregnancy . The high rate study particular ethnic group U.S . Presently , literature , describe new , efficient method diabetes prevention group high risk disorder , involve , lifestyle modification pharmacological therapy . Lifestyle intervention find reduce incidence type 2 diabetes 58 % metformin 31 % compare placebo . Studies need optimal postpartum long-term health woman GDM . Considerable recent evidence suggest incretin-based therapy may useful treatment DM2 continuous administration glucagon-like peptide 1 ( GLP-1 ) produce substantial improvement glucose control ß-cell function subject type 2 diabetes . Inhibition dipeptidyl peptidase-4 ( DPP-4 ) increase concentration GLP-1 may potentially delay disease progression GDM consider ß-cell function improvement DM2 ß-cell mass show increase animal model . This study examine combination sitagliptin-plus metformin effective metformin alone placebo improve metabolic parameter , specifically impact β-cell function , at-risk woman recent history GDM .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Females 18 year 42 year age experience gestational diabetes mellitus ( GDM ) recent ( within 12 month ) pregnancy prediabetic hyperglycemia determine oral glucose tolerance test ( OGTT ) 75 g glucose postpartum . Study subject inclusive prior GDM woman impair fast glucose ( IFG ) , impair glucose tolerance ( IGT ) , ( IFG/IGT ) postpartum . Written consent participation study Cholestasis past pregnancy Any hepatic disease past ( viral hepatitis , toxic hepatic damage , jaundice unknown etiology ) Serum aspartate transaminase ( AST ) and/or alanine aminotransferase ( ALT ) level exceed twice normal lab value Presence hypersensitivity sitagliptin DPP4 inhibitor Current use metformin , thiazolidinediones , GLP1 receptor agonist , DPP4 inhibitor , weight loss medication ( prescription counter [ OTC ] ) Prior use medication treat diabetes except gestational diabetes Use drug know exacerbate glucose tolerance History diabetes prior use medication treat diabetes except GDM Creatinine clearance le 60 ml/min Pregnancy plan come two year Currently lactate Patient willing use adequate contraception study period ( unless sterilize )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>prediabetes</keyword>
	<keyword>impaired fasting/impaired glucose tolerance</keyword>
	<keyword>post gestational diabetes</keyword>
	<keyword>diabetes prevention</keyword>
</DOC>